CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
V184 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03807843
NCT03807843Phase 2Completed
CompareCT.gov

Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in Previously Exposed Adults

Themis Bioscience GmbH·interventional·Posted Jan 17, 2019·Updated Sep 8, 2022

In Brief

A Phase 2 clinical trial evaluating V184 and Placebo for Chikungunya Virus Infection. Completed, enrolled 41 participants across 1 site.

Detailed Summary

Safety and immunogenicity of the investigational V184 chikungunya vaccine will be tested in participants with history of chikungunya infection. Initially 21 to 50 year old participants will be enrolled; after favorable review of safety data, participants aged 51 to 65 will be enrolled.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChikungunya Virus Infection
CountriesPuerto Rico
CollaboratorsWalter Reed Army Institute of Research (WRAIR)

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 17, 2019
Enrollment StartJul 16, 2019
Primary CompletionMay 13, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.5 years ago

Interventions

V184biological

Recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. Liquid frozen, life attenuated, measles vectored V184 vaccine administered via IM injection at 5 × 10\^5 TCID50 (+/- 0.5 log) per dose.

Placeboother

Sterile physiological saline for IM injection